Search

Your search keyword '"Rossello, R"' showing total 4 results
Start Over Author "Rossello, R" Journal oncology
4 results on '"Rossello, R"'

2. The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population

Author

Vincenzo Adamo, Mariangela Zanghì, Sergio Rizzo, Giuseppina Rosaria Rita Ricciardi, Antonio Russo, Giuseppa Ferraro, Tindara Franchina, Giuseppe Cicero, N. Caristi, Rosalba Rossello, Barbara Adamo, Adamo, V, Ricciardi, G, Adamo, B, Ferraro, G, Franchina, T, Rossello, R, Zanghi, M, Cicero, G, Rizzo, S, Caristi, N, and Russo, A

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Anthracycline, Settore MED/06 - Oncologia Medica, Receptor, ErbB-2, medicine.medical_treatment, Population, Antineoplastic Agents, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Ventricular Function, Left, Breast cancer, Elderly patients, Human epidermal growth factor receptor type 2, Trastuzumab, Internal medicine, medicine, Humans, Adverse effect, education, Geriatric Assessment, Aged, Retrospective Studies, Aged, 80 and over, Chemotherapy, Cardiotoxicity, education.field_of_study, business.industry, Retrospective cohort study, General Medicine, medicine.disease, Female, business, Elderly patient, medicine.drug
Abstract

Background: Breast cancer in the elderly is associated with high recurrence and death rates, due mostly to undertreatment. Human epidermal growth factor receptor type 2 (HER2) overexpression is infrequent in older patients. Trastuzumab-based chemotherapy is often withheld from elderly patients because of its cardiotoxicity. Patients and Methods: Medical records of consecutive HER2-positive breast cancer patients aged ≥70 years old treated between 2005 and 2010 in the participating centers were retrospectively reviewed. All patients underwent multidimensional geriatric assessment (MGA). Results: Among 59 patients identified, 51 patients were evaluable (median age 76 years). The rate of any adverse event was 20% (10/51). The most relevant cardiac adverse event consisted of symptomatic congestive heart failure (CHF; n = 1, 2%) followed by asymptomatic decreases of left ventricular ejection fraction (LVEF; n = 6, 12%). Other toxicities included moderate hypersensitivity reactions during trastuzumab infusions (n = 3, 6%). Hypertension, obesity, prior anthracyclines exposure and concurrent chemotherapy were associated with a higher incidence of toxic events. Previous radiotherapy, concurrent endocrine therapy and different trastuzumab-based regimens did not seem to influence toxicity. Conclusions: Our data suggest that trastuzumab has a good safety profile in nonfrail women aged 70 years and older. These favorable findings may be related to a limited number of anthracycline pretreatments, patient selection and a close cardiologic monitoring.

Published
2013
Full Text
View/download PDF

3. Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice?

Author

Fabi A, Ciccarese M, Scagnoli S, Russillo M, Schettini F, Buono G, Lorusso V, Cannita K, Arpino G, Stani S, Palleschi M, Rossello R, Sarobba G, Fabbri A, Giampaglia M, Pellegrini P, Adamo V, Morelli F, Barberi V, Ferretti G, Catania G, Pisegna S, Cognetti F, and Giannarelli D

Abstract

Background: To date, a consensus has not yet been reached about the therapy sequence after disease progression (PD) on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer (MBC)., Objectives: The present study assesses, in a real-world setting, the activity of different subsequent therapies in patients who experienced a PD on palbociclib (P) + endocrine therapy (ET), to evaluate the best therapy sequence., Methods: This is a multicenter retrospective observational study. Records of consecutive HR+/HER2- MBC patients from January 2017 to May 2019 were reviewed. The primary endpoint was the evaluation of progression-free survival (PFS) according to subsequent treatment lines after progression on P+ET. Toxicity data were also collected., Results: The outcomes were analyzed in 89 MBC patients that had progressed on previous P+ET: 17 patients were on hormone therapy (HT) and 31 patients on chemotherapy (CT) as second-line treatments; seven patients were on HT and 34 on CT as third-line therapies. PFS of patients treated with HT as second-line therapy is significantly improved when compared with patients treated with CT (p=0.01). Considering third-line settings, the difference in PFS was not statistically different between HT and CT. A better outcome in terms of toxicity is observed among HT patients for both second- and third-line therapies., Conclusions: patients who were progressive on P+ET could still benefit from a subsequent ET. In patients who experienced a good efficacy from prior ET, without visceral metastatic sites, HT seems the most suitable option, when compared to CT, also in terms of safety., (S. Karger AG, Basel.)

Published
2021
Full Text
View/download PDF

4. Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports.

Author

Giordano G, Febbraro A, Quaquarini E, Turletti A, Pedersini R, Raffaele M, Villa F, and Rossello R

Subjects
Adult, Breast Neoplasms metabolism, Breast Neoplasms pathology, Disease-Free Survival, Female, Humans, Liver metabolism, Liver pathology, Liver Neoplasms metabolism, Liver Neoplasms pathology, Middle Aged, Neoplasm Metastasis pathology, Receptor, ErbB-2 metabolism, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy, Furans therapeutic use, Ketones therapeutic use, Liver drug effects, Liver Neoplasms drug therapy, Neoplasm Metastasis drug therapy
Abstract

Liver metastases are very common in metastatic breast cancer (MBC); current treatments for these lesions are based on systemic chemotherapy, endocrine- or human epidermal growth factor receptor 2 (HER2)-targeted therapy, and palliative therapy. However, no standard approach has been clearly identified for second and further chemotherapy lines in MBC patients. In the phase III clinical trial EMBRACE, eribulin was particularly effective in reducing liver lesions and improving both overall survival and progression-free survival in liver MBC patients. In this series, we collected 8 case reports of Italian clinical practice in which eribulin has shown significant efficacy in reducing liver metastases in MBC patients: complete response was reported in 2 patients, and 4 patients achieved partial response. The treatment was well tolerated, thus confirming that eribulin is a suitable therapeutic option for elderly patients and for those who have metastatic HER2-negative disease. In the setting of MBC, the sequencing of therapeutic agents should consider expected response, side effects, tumor characteristics, and patient's preferences, in order to successfully tailor the most appropriate therapy beyond earlier lines., (© 2018 S. Karger AG, Basel.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results